TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6280836

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (1 vial of high viability Pasteur BCG by scarification technique on days 8 and 15 of each 21-28 day treatment cycle)
Number of subjects: 298

Group type: COMPARATOR
Intervention: No BCG immunotherapy
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (for patients who responded and survived longer than one year)
Number of subjects: 298

Group type: COMPARATOR
Intervention: No BCG immunotherapy (for patients who responded and survived longer than one year)
Number of subjects: 298
Study: 30573173

Group type: EXPERIMENTAL
Intervention: Group 1 (hip osteoarthritis)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Group 3 (healthy young women)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Group 2 (women without hip osteoarthritis)
Number of subjects: 125
Study: 27834225

Group type: EXPERIMENTAL
Intervention: Six-step approach with accompanying educational materials
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard information available (control group)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Six-step approach
Number of subjects: 230
Study: 25421470

Group type: EXPERIMENTAL
Intervention: Micafungin 2 mg/kg/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Micafungin 1 mg/kg/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Micafungin 3 mg/kg/day
Number of subjects: 229
Study: 24661464

Group type: EXPERIMENTAL
Intervention: Kinesia portable kinematic system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clinician ratings
Number of subjects: 18
Study: 21851025

Group type: EXPERIMENTAL
Intervention: Infusion therapy controlled by transesophageal dopplerography (Cardio Q apparatus)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Infusion therapy assessed clinically (BP, CVP, HR, diuresis)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Infusion therapy controlled by transesophageal dopplerography
Number of subjects: 72

Group type: COMPARATOR
Intervention: Infusion therapy assessed clinically
Number of subjects: 72
Study: 19321851

Group type: EXPERIMENTAL
Intervention: Fine arts visits (films, concerts, art exhibitions, singing in a choir) once a week for 8 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no fine arts visits during the trial)
Number of subjects: 101
Study: 17392668

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous morphine analgesia (control)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (intravenous morphine)
Number of subjects: 61
Study: 15147921

Group type: EXPERIMENTAL
Intervention: Environmental control education, allergen-proof encasements, pest extermination, and a HEPA air cleaner at the beginning of the study.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received the same intervention at the end of the study.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home environments, NO(2), O(3), airborne particulates, and allergens evaluated at baseline and at 6 and 12 months.
Number of subjects: 100
Study: 11216083

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Flecainide and Propafenone
Number of subjects: 352
Study: 9932219

Group type: EXPERIMENTAL
Intervention: Insulin Lispro (5 min before the meal)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Regular insulin (20 min before the meal)
Number of subjects: 7
Study: 8092452

Group type: EXPERIMENTAL
Intervention: midazolam, 0.2 mg/kg BW orally
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: nordazepam, 0.2 mg/kg BW orally
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: atropine, 0.5 mg, plus promethazine, 50 mg i.m.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: atropine, 0.5 mg, plus promethazine, 50 mg, plus pethidine, 0.7 mg/kg BW i.m.
Number of subjects: 38
Study: 2967711

Group type: EXPERIMENTAL
Intervention: sufentanil 5 micrograms kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: fentanyl 25 micrograms kg‐1
Number of subjects: 40
Study: 29438414

Group type: EXPERIMENTAL
Intervention: Higher baseline plasma PFAS concentrations (PFOS, PFOA, PFNA, PFHxS, PFDA)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Higher baseline plasma PFAS concentrations
Number of subjects: 621
Study: 28690076

Group type: EXPERIMENTAL
Intervention: Guideline-recommended care including reassurance, simple analgesia, and advice to stay active and avoid bed rest.
Number of subjects: 1643
Study: 26104013

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Typical American childhood diet (TACD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: TACD
Number of subjects: 33
Study: 23350053

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate
Number of subjects: 345

Group type: COMPARATOR
Intervention: Non-medicated group
Number of subjects: 345
Study: 21262880

Group type: EXPERIMENTAL
Intervention: Very Low Birth Weight (VLBW)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Term Birth
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Weight gain during the first 2 postnatal weeks
Number of subjects: 160
Study: 18922426

Group type: EXPERIMENTAL
Intervention: Levosimendan, 0.1 microg/kg/min, started after the induction of anesthesia (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levosimendan, 0.1 microg/kg/min, started immediately after the release of the aortic cross‐clamp (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Milrinone, 0.5 microg/kg/min, started after the release of the aortic cross‐clamp (Group A)
Number of subjects: 60
Study: 16539559

Group type: EXPERIMENTAL
Intervention: Transbond XT with BisCover varnished enamel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unite with BisCover varnished enamel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transbond XT without BisCover (dry enamel)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unite without BisCover (dry enamel)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transbond XT with no additional primer on BisCover
Number of subjects: 100
Study: 12820857

Group type: EXPERIMENTAL
Intervention: Cortisol (10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11208406

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg in 3x phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg in 2x phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg in once-daily phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg in once-daily phase
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8879340

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (cilazapril)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Beta‐adrenoceptor blocker (atenolol)
Number of subjects: 257
Study: 1642341

Group type: EXPERIMENTAL
Intervention: Serum thiopental concentration of 10-30 micrograms/ml for 5 min
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Higher serum thiopental concentration of 40-90 micrograms/ml
Number of subjects: 26
Study: 6380114

Group type: EXPERIMENTAL
Intervention: Herbazol A (with antacid component)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Herbacid B (without antacid component)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29351646

Group type: EXPERIMENTAL
Intervention: Postpartum training program (weekly supervised exercise class focusing on pelvic floor muscle strength training and daily home training)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Postpartum training program
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 29693865

Group type: EXPERIMENTAL
Intervention: Sildenafil monotherapy
Number of subjects: 30
Study: 23348043

Group type: EXPERIMENTAL
Intervention: Exercise group (EX) - core strengthening home exercise program thrice weekly for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study: 23706759

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg once or twice daily)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 278

Group type: COMPARATOR
Intervention: Vildagliptin and Placebo
Number of subjects: 278
Study: 20502283

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg orally twice daily for 5 days at the onset of bleeding)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (taken for 5 days at the onset of bleeding)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Doxycycline and Placebo
Number of subjects: 66
Study: 18556141

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with absorbed dose >1.0 Gy to the contralateral breast (CB)
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with absorbed dose to the contralateral breast (CB)
Number of subjects: 2107
Study: 16670154

Group type: EXPERIMENTAL
Intervention: 8% CHO solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 9
Study: 12792873

Group type: EXPERIMENTAL
Intervention: Killed whole-promastigote vaccine cocktail plus BCG adjuvant
Number of subjects: 48

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 48
Study: 10722770

Group type: EXPERIMENTAL
Intervention: Automated analysis of digitally recorded oximetry
Number of subjects: 246

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Polysomnography (PSG) with EEG based arousals
Number of subjects: 246
Study: 9187908

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP), 30 micrograms/day intranasally for 6 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oxybutynin alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oxybutynin plus Desmopressin (DDAVP)
Number of subjects: 114
Study: 8457502

Group type: EXPERIMENTAL
Intervention: 125 mg of oral acetazolamide (group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 54
Study: 3515419

Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional film‐based angiography alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined study (DSA and conventional angiography)
Number of subjects: 0
Study: 30075329

Group type: EXPERIMENTAL
Intervention: Aerobic exercise five days/week (supervised three days/week), 45 min/session, achieving 70-80% heart rate reserve
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual inactivity (Control)
Number of subjects: 212
Study: 26884081

Group type: EXPERIMENTAL
Intervention: Higher hs-cTnT levels
Number of subjects: 5407
Study: 24588813

Group type: EXPERIMENTAL
Intervention: Intensive pharmacist-managed intervention for 6 months
Number of subjects: 37
Study: 23784069

Group type: EXPERIMENTAL
Intervention: lpa bean high in PPs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: lpa bean low in PPs
Number of subjects: 20

Group type: COMPARATOR
Intervention: parent high in PPs
Number of subjects: 20

Group type: COMPARATOR
Intervention: parent low in PPs
Number of subjects: 20
Study: 21058884

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (stimulator tapping and regular massage twice a day for 4 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham auricular acupressure (tapping at sham points without massage stimulation)
Number of subjects: 33
Study: 18262041

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation during pregnancy
Number of subjects: 917

Group type: COMPARATOR
Intervention: Iron and folic acid (Control)
Number of subjects: 917
Study: 16606763

Group type: EXPERIMENTAL
Intervention: Trientine hydrochloride 500 mg 2 times per day plus 50 mg of zinc 2 times per day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate 20 mg 3 times per day with meals and 20 mg 3 times per day between meals plus 50 mg of zinc 2 times per day
Number of subjects: 48
Study: 12742878

Group type: EXPERIMENTAL
Intervention: Adolescent priming with alcohol self‐assessment and education just before health checkups (group 2)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Adolescent priming and provider prompting with the adolescent's self‐assessment and a patient education brochure (group 3)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Usual care (group 1)
Number of subjects: 444
Study: 10946883

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (200 mg/day for 2 weeks every 3 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 57
Study: 8610730

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 1428733

Group type: EXPERIMENTAL
Intervention: Vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day)
Number of subjects: 76
Study: 3897404

Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg/day for three consecutive days for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29219855

Group type: EXPERIMENTAL
Intervention: First and second surveys of hinge abduction assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Third and fourth surveys of hinge abduction assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: First and second readings of intraobserver agreement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Third and fourth readings of intraobserver agreement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Consensus sessions for diagnostic features
Number of subjects: 30
Study: 29362928

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:200,000 adrenaline
Number of subjects: 50

Group type: COMPARATOR
Intervention: amalgamated mixture of 2% lignocaine and 0.5% bupivacaine
Number of subjects: 50
Study: 27430123

Group type: EXPERIMENTAL
Intervention: APL-130277 10 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: APL-130277 (dosing up to 30 mg if needed)
Number of subjects: 19
Study: 25255346

Group type: EXPERIMENTAL
Intervention: Intranasal septal splints
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 60
Study: 23165660

Group type: EXPERIMENTAL
Intervention: Education, training, and technical support to promote use of a standard bed alarm system
Number of subjects: 27672

Group type: COMPARATOR
Intervention: Bed alarms available but not formally promoted or supported
Number of subjects: 27672
Study: 20097537

Group type: EXPERIMENTAL
Intervention: Low DHA intake (lowest tertile)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Highest tertile of DHA consumption
Number of subjects: 55
Study: 18620950

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine and amodiaquine
Number of subjects: 6758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6758

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT)
Number of subjects: 6758
Study: 19333052

Group type: EXPERIMENTAL
Intervention: Unroofing and marsupialization (UM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rhomboid excision and Limberg flap (RELP)
Number of subjects: 140
Study: 12845425

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft fixed with titanium screws
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Semitendinosus-bone composite (SBC) allograft fixed with bioabsorbable screws
Number of subjects: 7
Study: 11556655

Group type: COMPARATOR
Intervention: heparin 5,000 units s.c.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU without preservative s.c.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU without preservative i.v.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tinzaparin 12,250 anti‐Xa IU with preservative s.c.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU with preservative s.c.
Number of subjects: 30
Study: 9597562

Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8165070

Group type: EXPERIMENTAL
Intervention: Prenatal dexamethasone (DEX) treatment (6 mg four times at 12-hour intervals)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Prenatal dexamethasone (DEX) treatment combined with exogenous human surfactant therapy
Number of subjects: 157
Study: 3210111

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study: 30802718

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) using a portable device for 8 weeks (23 min/5 days/week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no EMS intervention)
Number of subjects: 19
Study: 28204733

Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 20% benzocaine
Number of subjects: 42
Study: 26580235

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 26
Study: 24867846

Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg (Frova)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 25 mg (FroDex25)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 37.5 mg (FroDex37.5)
Number of subjects: 314
Study: 22872107

Group type: EXPERIMENTAL
Intervention: Asha-Life intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 68
Study: 19244152

Group type: EXPERIMENTAL
Intervention: Psyllium supplementation (14 g/day for 3 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 86
Study: 17492348

Group type: EXPERIMENTAL
Intervention: 75 g of amino acids parenterally (Group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 150 g of amino acids parenterally (Group 2)
Number of subjects: 14
Study: 15618054

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) 4 g i.v. infusion for 8 hours starting immediately after the induction of anaesthesia (group D)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dextrose solution as placebo for 8 hours (group C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) infusion in patients with lower EF (below 38%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) infusion in patients with higher EF (above 38%)
Number of subjects: 45
Study: 12122920

Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists
Number of subjects: 0
Study: 10457621

Group type: EXPERIMENTAL
Intervention: Transfer-preparation letter and verbal explanation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no transfer-preparation letter)
Number of subjects: 50
Study: 8543357

Group type: EXPERIMENTAL
Intervention: Vancomycin at a concentration of 10 mg/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decontamination of the liquid culture before subculture on solid medium
Number of subjects: 0
Study: 2111629

Group type: EXPERIMENTAL
Intervention: Flow setting A (VFG of 75 ml.min‐1.kg‐1 and VE of 150 ml.min‐1.kg‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Flow setting B (VFG of 110 ml.min‐1.kg‐1 and VE of 175 ml.min‐1.kg‐1)
Number of subjects: 59
Study: 85583

Group type: EXPERIMENTAL
Intervention: Zinc administration (0.02 mg Zn per kg of body weight in the form of zinc sulphate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31043691

Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: sTNFR2 concentrations in the highest quartile within 6 weeks of delivery
Number of subjects: 326

Group type: COMPARATOR
Intervention: Daily TMP/SXT
Number of subjects: 326
Study: 28463010

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 65
Study: 25592287

Group type: EXPERIMENTAL
Intervention: Ethics rounds led by a philosopher/ethicist
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 2
Study: 24015717

Group type: EXPERIMENTAL
Intervention: Glucose solutions containing soy‐soluble polysaccharides (6%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose solutions containing flaxseed gum (0.7%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose solutions containing guar gum (0.23%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dairy‐based beverages with 0% or 1% soluble fiber added
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dairy‐based puddings with 0% or 1% soluble fiber added
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soy‐soluble polysaccharide‐fortified dairy products
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flaxseed gum‐fortified dairy products
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fiber‐fortified fluid and gelled dairy‐based study treatments
Number of subjects: 12
Study: 21357374

Group type: EXPERIMENTAL
Intervention: 30 min exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 min exercise
Number of subjects: 60
Study: 19603365

Group type: EXPERIMENTAL
Intervention: Multifunctional training including WBV (VTG)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Conventional training (TG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Wellness-control group (CG)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: VTG
Number of subjects: 151

Group type: COMPARATOR
Intervention: CG
Number of subjects: 151